A US district judge in Virginia ordered the Food and Drug Administration to reconsider its restrictions on mifepristone, finding them to be arbitrary and capricious. Judge Robert S Ballou noted that previous FDA reviews have consistently determined the abortion medication to be safe and effective, and instructed the agency to examine and consider overturning the barriers to access.
The case, Whole Woman’s Health Alliance v FDA, was filed in May 2023 by the Center for Reproductive Rights on behalf of abortion providers in Virginia, Kansas, and Montana. The plaintiffs sought removal of three restrictions, including requirements for special registration and certification of providers and pharmacies, as well as requirements for patients to complete what they characterized as duplicative and confusing paperwork.
The ruling comes as several states challenge mifepristone’s availability through separate court proceedings. The Fifth Circuit Court of Appeals is scheduled to hear arguments in a case where Louisiana seeks to reinstate previous restrictions that would prevent mail-order distribution and limit pharmacy prescriptions. The FDA, currently without a permanent commissioner, is conducting a review of abortion pill regulations that has been pushed by conservative lawmakers and activists.
Supporters of the ruling contend that the restrictions lack medical justification. Clinic operators stated that the requirements create delays and administrative burdens for patients traveling to access care in states where abortion is heavily restricted. Research indicates that mifepristone accounts for nearly two-thirds of all abortions in the US, with a quarter-century of studies supporting its safety and effectiveness. Legal experts caution that the decision will likely not conclude the broader policy debate surrounding mifepristone’s availability and regulatory requirements.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI